ZA201101938B - Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment - Google Patents

Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Info

Publication number
ZA201101938B
ZA201101938B ZA2011/01938A ZA201101938A ZA201101938B ZA 201101938 B ZA201101938 B ZA 201101938B ZA 2011/01938 A ZA2011/01938 A ZA 2011/01938A ZA 201101938 A ZA201101938 A ZA 201101938A ZA 201101938 B ZA201101938 B ZA 201101938B
Authority
ZA
South Africa
Prior art keywords
fgfr
inhibitors
treatment
methods
growth factor
Prior art date
Application number
ZA2011/01938A
Other languages
English (en)
Inventor
Haijun Sun
Ling Liu
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of ZA201101938B publication Critical patent/ZA201101938B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA2011/01938A 2008-10-20 2011-03-14 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment ZA201101938B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
ZA201101938B true ZA201101938B (en) 2012-08-29

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2011/01938A ZA201101938B (en) 2008-10-20 2011-03-14 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Country Status (17)

Country Link
US (3) US8043618B2 (enExample)
EP (1) EP2342232A2 (enExample)
JP (1) JP5577345B2 (enExample)
KR (1) KR101370798B1 (enExample)
CN (2) CN102186884B (enExample)
AR (1) AR073770A1 (enExample)
AU (1) AU2009307841B2 (enExample)
BR (1) BRPI0919832A8 (enExample)
CA (1) CA2741127C (enExample)
EA (1) EA021584B1 (enExample)
IL (1) IL211807A0 (enExample)
MX (1) MX2011004317A (enExample)
NZ (1) NZ592369A (enExample)
TW (1) TWI381848B (enExample)
UA (1) UA101681C2 (enExample)
WO (1) WO2010048026A2 (enExample)
ZA (1) ZA201101938B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
SG174904A1 (en) * 2009-03-25 2011-11-28 Genentech Inc Anti-fgfr3 antibodies and methods using same
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
CA2898415A1 (en) 2013-01-16 2014-07-24 Inserm (Institut National De La Sante Et De La Recherche Medicale) A soluble fibroblast growth factor receptor 3 (fgr3) polypeptide for use in the prevention or treatment of skeletal growth retardation disorders
HK1213180A1 (zh) 2013-03-06 2016-06-30 豪夫迈‧罗氏有限公司 治疗和预防癌症药物抗性的方法
TWI541022B (zh) 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
EP3151857A4 (en) * 2014-06-03 2018-04-18 Merck Sharp & Dohme Corp. Anti-blys antibodies
JP2017517552A (ja) 2014-06-13 2017-06-29 ジェネンテック， インコーポレイテッド 抗癌剤耐性の治療及び防止方法
CN111983536A (zh) * 2014-09-05 2020-11-24 海珀菲纳研究股份有限公司 低场磁共振成像系统的自动配置
MX392774B (es) 2014-09-26 2025-03-24 Janssen Pharmaceutica Nv Uso de paneles de genes mutantes de fgfr en la identificacion de pacientes con cancer que responderán al tratamiento con un inhibidor fgfr
AU2016219917B2 (en) * 2015-02-19 2021-12-16 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201711702A (zh) * 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
PL3481859T3 (pl) 2016-07-07 2022-07-11 Pfizer Inc. Rozpuszczalne polipeptydy receptora 3 czynnika wzrostu fibroblastów (sfgfr3) i ich zastosowania
WO2018129451A2 (en) * 2017-01-09 2018-07-12 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
JP2023538098A (ja) 2020-08-21 2023-09-06 ジェンザイム・コーポレーション Ｆｇｆｒ３抗体および使用の方法
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
WO2024107765A2 (en) * 2022-11-14 2024-05-23 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
US20240247069A1 (en) 2023-01-13 2024-07-25 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
WO1988009344A1 (en) 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
WO2002102973A2 (en) * 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
CA2550245A1 (en) * 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
KR20200058579A (ko) * 2006-06-06 2020-05-27 얀센 백신스 앤드 프리벤션 비.브이. 장내구균에 대한 사멸활성을 갖는 인간결합분자 및 그것의 용도
EA017203B1 (ru) * 2006-09-07 2012-10-30 Круселл Холланд Б.В. Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
AU2008317495B2 (en) * 2007-08-02 2013-08-01 Novimmune S.A. Anti-RANTES antibodies and methods of use thereof
CA2721052C (en) * 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Also Published As

Publication number Publication date
MX2011004317A (es) 2011-06-24
IL211807A0 (en) 2011-06-30
KR101370798B1 (ko) 2014-03-14
EA201170590A1 (ru) 2011-10-31
NZ592369A (en) 2013-02-22
AU2009307841A1 (en) 2010-04-29
JP5577345B2 (ja) 2014-08-20
BRPI0919832A8 (pt) 2019-01-08
BRPI0919832A2 (pt) 2015-12-15
US20100098696A1 (en) 2010-04-22
TWI381848B (zh) 2013-01-11
JP2012505912A (ja) 2012-03-08
WO2010048026A2 (en) 2010-04-29
US20120219563A1 (en) 2012-08-30
WO2010048026A3 (en) 2010-07-15
US20120009200A1 (en) 2012-01-12
US8404240B2 (en) 2013-03-26
CN102186884B (zh) 2014-08-13
TW201026325A (en) 2010-07-16
US8043618B2 (en) 2011-10-25
EP2342232A2 (en) 2011-07-13
CA2741127C (en) 2015-06-02
CN103524620A (zh) 2014-01-22
KR20110056554A (ko) 2011-05-30
AU2009307841B2 (en) 2013-09-12
US8182815B2 (en) 2012-05-22
EA021584B1 (ru) 2015-07-30
CA2741127A1 (en) 2010-04-29
AR073770A1 (es) 2010-12-01
UA101681C2 (ru) 2013-04-25
CN102186884A (zh) 2011-09-14

Similar Documents

Publication Publication Date Title
ZA201101938B (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
IL213068A0 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP2352452A4 (en) SYSTEMS AND METHOD FOR TREATING PROSTATE TISSUE
PL2352453T3 (pl) Układy i sposoby leczenia tkanki gruczołu krokowego
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
EP2019679A4 (en) GLUCOSE TRANSPORT AND APPLICATION METHOD
IL194820A0 (en) Devices and methods for treatment of tissue
ZA201100211B (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2249914A4 (en) IMPLANT EQUIPPED FOR NERVE LOCATION AND METHOD OF USE
SI2379096T1 (sl) Zaviralci TFPI in postopki uporabe
EP2170180A4 (en) METHOD AND DEVICES FOR TREATING VESSELS AND PROSTATE
IL212079A0 (en) Methods and devices for treating sleep apnea
GB0821927D0 (en) Article and method of surface treatment of an article
ZA201006293B (en) Composition and method for seed treatment use
PL2268292T3 (pl) Sposób i kompozycje do leczenia raka
EP2493550A4 (en) ELECTRO-OPTICAL FABRIC STIMULATOR AND METHOD OF USE THEREOF
IL220147A0 (en) Inhibitors of vascular endothelial growth factor (vegf) receptro and methods of use thereof
EP2376083A4 (en) QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
GB2463474B (en) Therapeutic bone growth and regeneration
WO2009151620A9 (en) Pain treatment using erk2 inhibitors
HK1156641A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
GB0800556D0 (en) Method of treatment and treatment therefor